A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

NCT05850286 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: anti-BCMA CAR-T
DRUG: VRD-based Regimen

Sponsor

Institute of Hematology & Blood Diseases Hospital, China